MEKTOVI is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test [see Dosage and Administration (2.1)].

2024年3月26日 · Mektovi (binimetinib) is an oral kinase inhibitor that may be used in combination with encorafenib for the treatment of adults with unresectable or metastatic melanoma or metastatic non-small cell lung cancer (NSCLC) with a confirmed BRAF mutation.

MEKTOVI® (binimetinib) This product information is intended only for residents of the United States. for Consumers: MEKTOVI U.S. Medication Guide; MEKTOVI - U.S. Medical Information Page - patient information, ways to contact Pfizer Medical & other resources; for Healthcare professionals: MEKTOVI U.S. Physician Prescribing Information

Binimetinib, sold under the brand name Mektovi, is an anti-cancer medication used to treat various cancers. [4] Binimetinib is a selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway. [5] Inappropriate activation of the pathway has been shown to occur in many cancers. [5]

See full prescribing information for MEKTOVI. MEKTOVI is a kinase inhibitor indicated: Melanoma. The recommended dose is 45 mg orally twice daily in combination with encorafenib. Take MEKTOVI with or without food. (2.2) NSCLC. The recommended dose is 45 mg orally twice daily in combination with encorafenib. Take MEKTOVI with or without food. (2.2)

MEKTOVI is a kinase inhibitor indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as...

2024年3月6日 · Mektovi is a brand-name oral tablet that’s prescribed for certain types of cancer. Mektovi contains the active ingredient binimetinib. Mektovi is FDA approved to treat the …